ISI Group biotech analyst Mark Schoenebaum held a lunch meeting Friday for 120 investors to discuss the current state of hepatitis C drug development. As part of his meeting, Schoenebaum surveyed his investor audience -- made up of 30% generalists, 20% arbs and 30% specialists -- on their views and opinions about the current red-hot topics in hepatitis C.
Asked if Idenix Pharma has a greater than 50% chance of being acquired, 79% of the investors responded in the affirmative, 21% said no.
The group was more evenly split on Achillion Pharmaceuticals' (ACHN) chances for a takeout, with 49% leaning yes and 51% saying no.Gilead Science's (GILD - Get Report) $11 billion acquisition of Pharmasset was the spark that ignited the recent run in Hep C drug stocks. Schoenebaum's buy-side investor crowd likes the blockbuster deal, with 64% predicting Gilead will create value with its purchase of Pharmasset. Thirty-six percent say Gilead is going to destroy shareholder value with this deal. On a related note, 61% say Gilead shares are a buy today.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.